| Identification | Back Directory | [Name]
1,2,4-Oxadiazolidine-3,5-dione, 2,2'-[(2Z)-2-butene-1,4-diylbis(oxy-4,1-phenylenemethylene)]bis- | [CAS]
163300-58-1 | [Synonyms]
1,2,4-Oxadiazolidine-3,5-dione, 2,2'-[(2Z)-2-butene-1,4-diylbis(oxy-4,1-phenylenemethylene)]bis- | [Molecular Formula]
C22H20N4O8 | [MOL File]
163300-58-1.mol | [Molecular Weight]
468.42 |
| Hazard Information | Back Directory | [Description]
YM-440 is an insulin sensitizer potentially for the treatment of type 2 diabetes. Through research, it has proven to be a novel hypoglycemic agent by suppressing hepatic glucose output via gluconeogenesis by reducing glucose-6-phosphatase activity in obese Zucker rats. | [Uses]
YM440 is an orally active oxadiazolidinedione analog. YM440 ameliorates hyperglycemia without changing PPARy activity, adipocyte differentiation, or fat weight. YM440 is used in the study for non-insulin-dependent diabetes mellitus (NIDDM)[1]. | [in vivo]
YM440 (100 mg/kg, orally, daily for 28 days, db/db mice) increases hepatic glucokinase expression but not adipose tissue FABP and UCP1 expression, indicating a tissue selective expression of PPARγ-related genes[2].
| [References]
[1] A Shimaya, et al. The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice. Metabolism. 2000 Mar;49(3):411-7. DOI:10.1016/s0026-0495(00)90440-2
[2] Eiji Kurosaki, et al. Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation. Biochem Pharmacol. 2003 Mar 1;65(5):795-805. DOI:10.1016/s0006-2952(02)01617-9 |
|
|